Dispute on the insurance price of Glivec is still far from being settled

Even in the midst of the growing disaccords over the insurance prices of Glivec between civil organizations and Novartis Korea, both parties are still repeating their own claims and to make matters worse, the situation becomes more bleak due to the government's lukewarm attitude.

The Joint Committee for Glivec (JCG), which is also designed to expand the public use of drug, showed its firm st...